Dopamine, ROSC, and runs of VT

This is a challenging scenario because you're balancing two competing priorities:

1. Maintaining adequate perfusion after ROSC
2. Avoiding recurrent ventricular arrhythmias

From the case you've described, the patient's recurrent VT may have been related to a combination of factors:

• Post-ROSC myocardial ischemia
• Acute myocardial infarction
• Severe acute heart failure/flash pulmonary edema
• Hypoxia/acidosis
• Electrolyte disturbances
• High sympathetic state
• Potential contribution from dopamine at 15 mcg/kg/min

Firstly, let’s look at dopamine. At doses below 5 mcg/kg/min, dopamine binds primarily to dopamine-1 receptors in the renal and mesenteric (gut) vasculature. These receptors respond by dilating blood vessels in those regions, increasing blood flow to the kidneys and intestines; the cardiovascular effects at this stage are modest.

Between roughly 5 and 10 mcg/kg/min, dopamine starts activating beta-1 adrenergic receptors in the heart. Heart rate increases (chronotropy), the heart contracts more forcefully (inotropy) and cardiac output climbs. This is where dopamine starts looking more like a cardiac stimulant, useful for treating cardiogenic shock where the heart isn’t pumping effectively.

Above 10 mcg/kg/min, alpha-1 adrenergic receptors enter the picture. These receptors, primarily in peripheral blood vessels, respond by constricting, raising systemic vascular resistance and blood pressure. At this point, dopamine is essentially a vasoconstrictor. The renal benefits from the dopaminergic phase are often overwhelmed or reversed as blood is shunted away from the kidneys under intense sympathetic stimulation.

Secondly, let’s look at patient management. If the patient develops recurrent VT/VF after ROSC, we could think beyond simply "restart the dopamine because the BP is low." A key question we can ask ourselves: Is the hypotension primarily due to vasodilation, pump failure, or both? In a patient with flash pulmonary edema, the hypotension is often related to significant LV dysfunction/cardiogenic shock, not a volume deficit.

Something to consider is a patch to a base hospital physician. You could have a conversation regarding this very dynamic and complex patient about treatment that aims more at better perfusion such as a MAP≥65 mmHg with a possible lower SBP, one that is simply sufficient for perfusion. Currently the ALS PCS does recommend attempting to reach an SBP of ≥90 mmHg, but for this specific patient there could be other treatment ideas that a BHP could offer. Additionally, you could discuss low doses of Lidocaine or Amiodarone as an antiarrhythmic agent to further help with the tachydysrhythmia. Engaging with a BHP early on in the treatment plan is exactly the type of complex hemodynamic situation where individualized physician guidance is valuable.

If recurrent VT appears possibly related to escalating dopamine doses, it would be reasonable to recognize dopamine, as you mentioned, as pro-arrhythmic like many pressors, and as a possible contributor to the arrythmia. You could consider lowering the dose to 10mcg/kg/min to work more on the chronotropy and inotropy rather than the vasoconstriction properties at 15mcg/kg/min.